EPSC Reprogramming
The world's first Expanded Potential Stem Cells (EPSCs) technology, possessing totipotent differentiation capability (including all three embryonic germ layers and extra-embryonic trophoblast cells).
EPSC Pluripotent Stem Cell Medium
Proprietary chemically limited medium (serum free)
Patent Portfolio
Core patents cover China, the U.S., Japan, and Europe (WO 2020/200071 A1)
Technical Advantages
-
Totipotency: EPSCs can differentiate into all cell types in both embryonic and extra-embryonic tissues, providing a broad application prospect for regenerative medicine.
-
Efficient gene editing: Streamlined process enabling knockout, knock-in, and point mutations, speeding up disease model development and drug screening.
-
High Stability: Comparable quality to embryonic stem cells (ESCs), with low heterogeneity, ensuring consistency in experiments and treatments.
-
Low-Cost Mass Production: Reduces production time by 50% and costs by 30%, enhancing market competitiveness and promoting technology adoption.
